India
· Delayed Price · Currency is INR Glenmark Life Sciences Statistics
Total Valuation
Glenmark Life Sciences has a market cap or net worth of INR 144.34 billion. The enterprise value is 141.49 billion.
| Market Cap | 144.34B |
| Enterprise Value | 141.49B |
Important Dates
The next estimated earnings date is Friday, October 25, 2024.
| Earnings Date | Oct 25, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Glenmark Life Sciences has 122.53 million shares outstanding. The number of shares has increased by 0.17% in one year.
| Shares Outstanding | 122.53M |
| Shares Change (YoY) | +0.17% |
| Shares Change (QoQ) | -0.08% |
| Owned by Insiders (%) | 0.00% |
| Owned by Institutions (%) | 5.27% |
| Float | 30.63M |
Valuation Ratios
The trailing PE ratio is 32.35 and the forward PE ratio is 26.91. Glenmark Life Sciences's PEG ratio is 1.63.
| PE Ratio | 32.35 |
| Forward PE | 26.91 |
| PS Ratio | 6.29 |
| PB Ratio | 6.19 |
| P/FCF Ratio | n/a |
| PEG Ratio | 1.63 |
Enterprise Valuation
| EV / Earnings | 31.66 |
| EV / Sales | 6.17 |
| EV / EBITDA | 22.02 |
| EV / EBIT | 24.17 |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.01 |
| Debt / EBITDA | 0.03 |
| Debt / FCF | n/a |
| Interest Coverage | 389.45 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Capital (ROIC) | 16.23% |
| Revenue Per Employee | 11.39M |
| Profits Per Employee | 2.22M |
| Employee Count | 2,014 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +88.90% in the last 52 weeks. The beta is 0.16, so Glenmark Life Sciences's price volatility has been lower than the market average.
| Beta (5Y) | 0.16 |
| 52-Week Price Change | +88.90% |
| 50-Day Moving Average | 1,082.63 |
| 200-Day Moving Average | 881.27 |
| Relative Strength Index (RSI) | 56.08 |
| Average Volume (20 Days) | 275,186 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Glenmark Life Sciences had revenue of INR 22.93 billion and earned 4.47 billion in profits. Earnings per share was 36.41.
| Revenue | 22.93B |
| Gross Profit | 12.52B |
| Operating Income | 5.85B |
| Pretax Income | 6.00B |
| Net Income | 4.47B |
| EBITDA | 6.43B |
| EBIT | 5.85B |
| Earnings Per Share (EPS) | 36.41 |
Balance Sheet
The company has 3.02 billion in cash and 171.48 million in debt, giving a net cash position of 2.84 billion or 23.21 per share.
| Cash & Cash Equivalents | 3.02B |
| Total Debt | 171.48M |
| Net Cash | 2.84B |
| Net Cash Per Share | 23.21 |
| Equity (Book Value) | 23.32B |
| Book Value Per Share | 190.28 |
| Working Capital | n/a |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 54.58%, with operating and profit margins of 25.52% and 19.49%.
| Gross Margin | 54.58% |
| Operating Margin | 25.52% |
| Pretax Margin | 26.14% |
| Profit Margin | 19.49% |
| EBITDA Margin | 28.02% |
| EBIT Margin | 25.52% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 22.50, which amounts to a dividend yield of 1.87%.
| Dividend Per Share | 22.50 |
| Dividend Yield | 1.87% |
| Dividend Growth (YoY) | 314.29% |
| Years of Dividend Growth | 1 |
| Payout Ratio | n/a |
| Buyback Yield | -0.17% |
| Shareholder Yield | 1.70% |
| Earnings Yield | 3.09% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |